The luteinizing hormone beta-subunit exon 3 (Gly102Ser) gene mutation and ovarian responses to controlled ovarian hyperstimulation
- PMID: 25469124
- PMCID: PMC4248152
The luteinizing hormone beta-subunit exon 3 (Gly102Ser) gene mutation and ovarian responses to controlled ovarian hyperstimulation
Abstract
Background: Despite extensive progress in IVF techniques, one of the most difficult problems is the variability in the response to controlled ovarian hyperstimulation (COH). Recent studies show the effects of individual genetic variability on COH outcome.
Objective: To evaluate the correlation between LHβ G1502A polymorphisms in exon 3 of the LH gene and ovarian response to COH.
Materials and methods: A total of 220 women treated with a long protocol for ovarian stimulation were studied. Three genotypes of GG, GA and AA were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.
Results: In total, 34 (17%) patients were poor responders, 154 (77%) were normal responders and 12 (6%) were hyper responders. The most frequent genotype was GA (55.5%) whereas 44.5% of patients showed GG genotype and there was no patient with AA genotype. In total 54.5% of normal responders, 61.8% of poor responders and 50% of hyper responders showed GA genotype.
Conclusion: Our results did not establish a significant relationship between this polymorphism and the ovarian response. Therefore it is still very difficult to use the genotype of patients for prediction of the ovarian response to stimulation.
Keywords: LHβgene; Ovulationinduction; Singlenucleotidepolymorphisms.
Similar articles
-
Investigating the association between polymorphism of follicle-stimulating hormone receptor gene and ovarian response in controlled ovarian hyperstimulation.J Hum Reprod Sci. 2011 May;4(2):86-90. doi: 10.4103/0974-1208.86089. J Hum Reprod Sci. 2011. PMID: 22064672 Free PMC article.
-
Evaluating influence of the genotypes in the follicle-stimulating hormone receptor (FSHR) Ser680Asn (rs6166) polymorphism on poor and hyper-responders to ovarian stimulation: a meta-analysis.J Ovarian Res. 2014 Dec 20;7:285. doi: 10.1186/s13048-014-0122-2. J Ovarian Res. 2014. PMID: 25526787 Free PMC article.
-
Luteinizing hormone beta-subunit gene (LHbeta) polymorphism in infertility and endometriosis-associated infertility.Eur J Obstet Gynecol Reprod Biol. 2010 Jul;151(1):66-9. doi: 10.1016/j.ejogrb.2010.03.022. Epub 2010 Apr 28. Eur J Obstet Gynecol Reprod Biol. 2010. PMID: 20430510
-
Genetic predictors of controlled ovarian hyperstimulation: where do we stand today?Hum Reprod Update. 2011 Nov-Dec;17(6):813-28. doi: 10.1093/humupd/dmr034. Epub 2011 Aug 23. Hum Reprod Update. 2011. PMID: 21862569 Review.
-
Choosing the right stimulation protocol for in vitro fertilization-embryo transfer in poor, normal, and hyper-responders.Clin Exp Obstet Gynecol. 2011;38(4):313-7. Clin Exp Obstet Gynecol. 2011. PMID: 22268260 Review.
Cited by
-
The average gonadotrophin dosage per follicle is predictive of ovarian response and cumulative live birth chances after in vitro fertilization: a retrospective cohort study.BMC Womens Health. 2023 Feb 4;23(1):45. doi: 10.1186/s12905-023-02195-5. BMC Womens Health. 2023. PMID: 36739381 Free PMC article.
-
The effect of Myo-Inositol supplement on molecular regulation of folliculogenesis, steroidogenesis, and assisted reproductive technique outcomes in patients with polycystic ovarian syndrome.Mol Biol Rep. 2022 Feb;49(2):875-884. doi: 10.1007/s11033-021-06833-9. Epub 2022 Jan 18. Mol Biol Rep. 2022. PMID: 35040006
-
Pharmacogenomic of LH and its receptor: are we ready for clinical practice?Reprod Biol Endocrinol. 2025 Feb 25;23(Suppl 1):29. doi: 10.1186/s12958-025-01359-2. Reprod Biol Endocrinol. 2025. PMID: 40001128 Free PMC article. Review.
References
-
- Society for Assisted Reproductive Technology; American Society for Reproductive Medicine. Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/ Society for Assisted Reproductive Technology registry. Fertil Steril. 2007;87:1253–1266. - PubMed
-
- Verberg MF, Eijkemans MJ, Macklon NS, Heijnen EM, Baart EB, Hohmann FP, et al. The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis. Hum Reprod Update. 2009;15:5–12. - PubMed
-
- Yong PY, Brett S, Baird DT, Thong KJ. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertil Steril. 2003;79:308–315. - PubMed
-
- Out HJ, Rutherford A, Fleming R, Tay CC, Trew G, Ledger W, et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Hum Reprod. 2004;19:90–95. - PubMed
-
- Themmen AP. An update of the pathophysiology of human gonadotrophin subunit and receptor gene mutations and polymorphisms. Reproduction. 2005;130:263–274. - PubMed
LinkOut - more resources
Full Text Sources
Medical